The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Subscribe To Our Newsletter & Stay Updated
